Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiff Oncology (CRDF – Research Report) and AbCellera Biologics (ABCL – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Cardiff Oncology (CRDF)

William Blair analyst Andy Hsieh reiterated a Buy rating on Cardiff Oncology today. The company’s shares closed last Tuesday at $1.70.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 11.5% and a 47.1% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Aardvark Therapeutics, Inc., and Corbus Pharmaceuticals. ;'>

Cardiff Oncology has an analyst consensus of Strong Buy, with a price target consensus of $11.00.

See Insiders’ Hot Stocks on TipRanks >>

AbCellera Biologics (ABCL)

In a report released yesterday, Brendan Smith from TD Cowen maintained a Buy rating on AbCellera Biologics. The company’s shares closed last Tuesday at $3.22.

According to TipRanks.com, Smith is a 3-star analyst with an average return of 2.9% and a 45.1% success rate. Smith covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Ginkgo Bioworks Holdings, and Cytek Biosciences. ;'>

The the analyst consensus on AbCellera Biologics is currently a Moderate Buy rating.

Disclaimer & DisclosureReport an Issue